These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29927668)

  • 1. Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells - is a new era coming?
    Okla K; Wertel I; Wawruszak A; Bobiński M; Kotarski J
    Crit Rev Clin Lab Sci; 2018 Sep; 55(6):376-407. PubMed ID: 29927668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
    Haber DA; Velculescu VE
    Cancer Discov; 2014 Jun; 4(6):650-61. PubMed ID: 24801577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis.
    De Rubis G; Rajeev Krishnan S; Bebawy M
    Trends Pharmacol Sci; 2019 Mar; 40(3):172-186. PubMed ID: 30736982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research.
    Silvestris N; Ciliberto G; De Paoli P; Apolone G; Lavitrano ML; Pierotti MA; Stanta G;
    J Exp Clin Cancer Res; 2017 Sep; 36(1):128. PubMed ID: 28903768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine.
    Shang M; Ji JS; Song C; Gao BJ; Jin JG; Kuo WP; Kang H
    Methods Mol Biol; 2017; 1660():1-14. PubMed ID: 28828643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine.
    Alberter B; Klein CA; Polzer B
    Expert Rev Mol Diagn; 2016; 16(1):25-38. PubMed ID: 26567956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
    Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
    Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of liquid biopsy in precision medicine: opportunities and challenges.
    Wang J; Chang S; Li G; Sun Y
    Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-Based Methods for Detection of Circulating Tumor Cells and Their Potential for Personalized Diagnostics.
    Zamay AS; Zamay GS; Kolovskaya OS; Zamay TN; Berezovski MV
    Adv Exp Med Biol; 2017; 994():67-81. PubMed ID: 28560668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy.
    Schlange T; Pantel K
    Pharmacogenomics; 2016 Feb; 17(3):183-6. PubMed ID: 26799583
    [No Abstract]   [Full Text] [Related]  

  • 15. [Liquid biopsy: a possible approach for cancer screening].
    Thierry AR; Tanos R
    Med Sci (Paris); 2018 Oct; 34(10):824-832. PubMed ID: 30451677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells in breast cancer: applications in personalized medicine.
    Lee JS; Magbanua MJM; Park JW
    Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores].
    Perrier A; Hainaut P; Lamy PJ; Guenoun A; Nguyen DP; Guerber F; Troalen F; Denis JA; Boissan M
    Bull Cancer; 2022 Feb; 109(2):151-169. PubMed ID: 35012767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsies in Oncology and the Current Regulatory Landscape.
    Strotman LN; Millner LM; Valdes R; Linder MW
    Mol Diagn Ther; 2016 Oct; 20(5):429-36. PubMed ID: 27324559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.